glp-1 super responders Hyper-Responders: The Good, The Bad, and The Truth | Dr. Dan The GLP-1 Super Responder Playbook

However, it did not affect risk of heart failure or myocardial reinfarction [3][33]

These findings indicate that loss of CI in adipocytes includes lipid storage capacity in adipose tissue and systemic metabolic homeostasis

References: A Brave New World: Therapeutic Area Deep Dives on Obesity This blog is part of a new series exploring a range of topics in the obesity market, including: market size and scope, impact of payer controls, activity in non-traditional channels, patient behavior, GLP-1 impact, HCP responses, the policy landscape, pharmacy economics, and the outlook for the future of GLP-1

Wegovy (semaglutide): 7% of adults taking the 2.4 mg dose, and 4% of pediatric patients 12 years and older taking the 2.4 mg dose